| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 3rd February 2021 | Gisela Schwab | 9,745 | Grant/award etc. | $0.00 | |
| 3rd February 2021 | Michael Morrissey | 23,238 | Grant/award etc. | $0.00 | |
| 3rd February 2021 | Michael Morrissey | 65,190 | Payment by withholding | $22.56 | $1,470,686.40 |
| 3rd February 2021 | Christopher J. Senner | 59,411 | Grant/award etc. | $0.00 | |
| 3rd February 2021 | Christopher J. Senner | 9,745 | Grant/award etc. | $0.00 | |
| 3rd February 2021 | Gisela Schwab | 14,982 | Payment by withholding | $22.56 | $337,993.92 |
| 3rd February 2021 | Peter Lamb | 71,293 | Grant/award etc. | $0.00 | |
| 3rd February 2021 | Peter Lamb | 9,370 | Grant/award etc. | $0.00 | |
| 3rd February 2021 | Gisela Schwab | 71,293 | Grant/award etc. | $0.00 | |
| 3rd February 2021 | Christopher J. Senner | 18,206 | Payment by withholding | $22.56 | $410,727.36 |
Exelixis
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 6/10.
Exelixis, Inc. engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994.
Ticker: EXEL
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 939767
Employees: 484
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $527 M (0%)
Receivables, Net, Current: $121 M (1%)
Inventory, Net: $17 M (28%)
Assets, Current: $1 B (37%)
Property, Plant and Equipment, Net: $52 M (7%)
Other Assets, Noncurrent: $61 M (13%)
Assets: $2 B (8%)
Accounts Payable, Current: $9 M (-21%)
Liabilities, Current: $143 M (0%)
Other Liabilities, Noncurrent: $7 M (207%)
Liabilities: $213 M (6%)
Common Stock, Value, Issued: $309 Th (1%)
Common Stock, Shares, Issued: $309 M (1%)
Retained Earnings (Accumulated Deficit): $444 M (-20%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $8 M (155%)
Stockholders' Equity (Parent): $2 B (0%)
Liabilities and Equity: $2 B (8%)
Revenue: $259 M (-46%)
Cost of Revenue: $9 M (-50%)
Research and Development: $115 M (-46%)
Operating Income/Loss: $76 M (-41%)
Income before taxes: $81 M (-42%)
Provision for income taxes: $14 M (-45%)
EPS (basic): $0.22 (0%)
EPS (diluted): $0.21 (0%)
News
Exelixis, Inc. 2020 Q4 - Results - Earnings Call Presentation
10th February 2021